The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | Targeting less common mutations in colorectal cancer
Sebastian Stintzing, MD, Charite University Hospital, Berlin, Germany, discusses targeting rare genetic alterations in patients with colorectal cancer. The Phase II MOUNTAINEER trial (NCT03043313) and the Phase II DESTINY-CRC01 trial (NCT03384940) assessed tucatinib with trastuzumab and trastuzumab deruxtecan respectively in patients with HER2-expressing metastatic colorectal cancer. More common mutations such as EFGR, RAS and BRAF are initially tested for first and next-generation sequencing (NGS) can take place upon relapse to detect rarer mutations such as NTRK and KRAS G12C. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3ZWhLDH
